Antipsychotics

New research reveals that patients are often not given fully informed consent before being prescribed antipsychotics.

Only 4 of 188 antipsychotic trials assessed blinding, and in all 4 cases, the blind was broken, potentially leading to an overestimation of the drug effect.

Antipsychotic medications that are commonly being used to help control behaviors in elderly people with dementia seem to be causing premature deaths at high rates.

A review of the scientific literature related to the withdrawal of antipsychotics: animal studies, withdrawal symptoms, tapering success rates, and consumer accounts of discontinuation.

The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.

Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

20-year follow-up study finds that after four years, patients not prescribed antipsychotics have significantly better work functioning.

Long-term treatment with antipsychotic drugs is currently considered the standard treatment for patients diagnosed with ‘schizophrenia.’ A new study challenges this practice, however. The...

“Patients expressed feeling unaccepted by society or uncomfortable in their own skin… A few indicated that they would rather be dead than have tardive dyskinesia.”

Common second-generation antipsychotic medications are causing symptoms of obsessive-compulsive disorder to emerge in many people who previously only had schizophrenia symptoms, according to a...

People who take antipsychotic medications experience many side effects which have "major disruptive impact on their lives," according to research in the Journal of Mental Health Nursing.

Children as young as four in foster care are taking three or more psychotropic medications, and the length of time that children aged six...

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.

The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.

A study, recently published in Psychological Medicine, examined the cognitive functioning of individuals with schizophrenia who discontinued antipsychotics, and those who maintained their antipsychotic...

This guide, by psychiatrists Volkmar Aderhold and Peter Stastny, provides a comprehensive review of antipsychotics and an evidence-based rationale for avoiding their use in first-episode psychosis, and for minimizing their long-term use.

Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.

The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

Four different studies conducted in different ways examining different groups have linked use of certain psychiatric drugs to bone fracture risks and negative impacts on human bone development.

New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.

New research examines service user attitudes on discontinuing and reducing antipsychotic drugs.